Related Experiment Video
Updated: Mar 22, 2026
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Cystatin C as a Predictor of In-Hospital Mortality After Exacerbation of COPD
Guoping Hu1, Yankui Wu2, Yumin Zhou3
1Department of Respiratory Medicine, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Insights
Cystatin C (CysC) is a strong predictor of in-hospital mortality in patients experiencing a Chronic Obstructive Pulmonary Disease (COPD) exacerbation. Higher CysC levels indicate a significantly increased risk of death during hospitalization for COPD.
Area of Science:
- Pulmonary Medicine
- Nephrology
- Cardiology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is frequently linked with cardiovascular and renal complications.
- Cystatin C (CysC) serves as a key biomarker for renal function and is an independent predictor of mortality in elderly individuals.
- The prognostic significance of CysC for in-hospital mortality in COPD exacerbation patients requires further investigation.
Purpose of the Study:
- To evaluate the prognostic value of serum Cystatin C (CysC) levels in predicting in-hospital mortality among patients admitted for a COPD exacerbation.
- To identify CysC as an independent risk factor for mortality in this patient population.
Main Methods:
- Serum CysC levels and arterial blood gas analyses were measured in 477 patients with COPD exacerbation.
- Receiver operating characteristic (ROC) curve analysis determined the optimal CysC threshold for mortality prediction.
- Univariate and multiple logistic regression analyses identified independent predictors of in-hospital mortality, with subgroup analyses accounting for comorbidities.
Main Results:
- The in-hospital mortality rate was 12.4% (59 deaths).
- Patients who died had significantly lower pH, higher CysC, higher PaCO2, and lower PaO2 levels compared to survivors.
- CysC levels ≥1.59 mg/L were strongly associated with increased in-hospital mortality (RR=5.49), and CysC emerged as an independent predictor alongside low pH and heart failure.
Conclusions:
- Serum Cystatin C is a potent and independent risk factor for hospital mortality in patients with COPD exacerbation.
- CysC measurement can aid in risk stratification and management of patients hospitalized for COPD.
- These findings highlight the interconnectedness of respiratory, renal, and cardiovascular health in COPD outcomes.
Background:
COPD is associated with cardiovascular and renal dysfunction. Cystatin C (CysC) is a biomarker of renal function and an independent risk factor for all-cause and cardiovascular mortality among elderly persons. The aim of the study was to examine the prognostic role of CysC for in-hospital mortality in subjects with a COPD exacerbation.
Methods:
Upon admission, serum CysC levels and arterial blood gas analysis from 477 subjects with a COPD exacerbation were measured. Clinical characteristics were also recorded. A receiver operating characteristic curve analysis was used to determine the level of CysC that discriminated survivors from non-survivors. Univariate and multiple logistic regression analyses were used to identify the risk factors for in-hospital mortality. To reduce the influence of confounders, subgroup analyses were performed according to the comorbidities, including states of heart failure, renal dysfunction, and pH, PaCO2 , and PaO2 levels.
Results:
During the in-hospital period, 59 subjects died, and 418 subjects recovered. The decedent group showed lower pH (7.27 ± 0.17 vs 7.38 ± 0.06, P < .001), higher CysC (2.21 ± 1.05 mg/L vs 1.39 ± 0.54 mg/L, P < .001), higher PaCO2 (77 ± 39 mm Hg vs 48 ± 14 mm Hg, P < .001), and lower PaO2 (74 ± 32 mm Hg vs 84 ± 26 mm Hg, P < .001) levels. The area under the receiver operating characteristic curve for the CysC prediction of death was 0.77 (95% CI 0.70-0.84). CysC values ≥1.59 mg/L were associated with significantly higher in-hospital mortality (relative risk = 5.49, 95% CI 3.24-9.32, P < .001). Multiple logistic regression analysis showed that pH <7.20, CysC ≥1.59 mg/L, and heart failure were independent predictors of in-hospital mortality. The subgroup analysis showed that the comorbid states of renal dysfunction, congestive heart failure, and the levels of pH, PaCO2 , and PaO2 did not alter the conclusion that CysC was a mortality risk factor for subjects with a COPD exacerbation.
Conclusion:
CysC was a strong and independent risk factor for hospital mortality secondary to COPD exacerbation.
More Related Videos
07:38Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
Published on: August 3, 2021
06:57The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...